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Abstract
Background: Ablation for ≤ 3-cm hepatocellular carcinoma (HCC) has been demonstrated to be an
effective treatment strategy. The present study sought to examine the outcomes of patients with
≤3 cm HCC after ablation versus resection.
Methods: Patients treated by ablation or surgical resection for ≤ 3 cm T1 HCC were identified from
the National Cancer Database (2002–2011). Survival outcomes were analysed according to propensity
score modelling.
Results: A total of 2804 patients underwent ablation (n = 1984) or a resection (n = 820) for solitary
HCC ≤ 3 cm. Patients treated with ablation as compared with a resection had a higher frequency in
alpha-fetoprotein level (AFP) elevation (46.5% versus 39.1%, P < 0.01) and the presence of cirrhosis
(22.2% versus 14.5%, P < 0.01). Unadjusted overall survival (OS) at 3 and 5 years was greater after a
resection (67%, 55%) versus ablation (52%, 36%, P < 0.01). After propensity score matching, the
improved overall survival (OS) was sustained among the resection cohort (5 year OS: 54% versus
37%, P < 0.001). In multivariable models, a resection was independently associated with an improved
OS [hazard ratio (HR): 0.62, 95% confidence interval (CI): 0.48–0.81; P < 0.01].
Conclusion: Resection of HCC ≤ 3 cm results in better long-term survival as compared with ablation.
Treatment strategies for small solitary HCC should emphasize a resection first approach, with ablation
being reserved for patients precluded from surgery.
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Introduction
Current treatment algorithms for hepatocellular carcinoma
(HCC) have been largely influenced by the Barcelona Clinic
Liver Cancer (BCLC) staging system, which takes into account
both patient- and tumour-related factors, when deciding the
optimal therapy to pursue.1 In the setting of early stage HCC,
liver transplantation, hepatic resection (HR), or ablative thera-
pies are considered curative approaches for this disease.2 How-
ever, the relative scarcity of suitable organs has limited the
dissemination of liver transplantation, which continues to
result in the best long-term outcomes. Instead, most patients
are offered HR or ablation as first-line therapies for early stage
HCC.
Over the last decade, there continues to be an ongoing
debate over the best therapeutic option, either HR versus abla-
tion, for small HCC lesions. In the most recent treatment
guidelines proposed by the American Association for the Study
of Liver Diseases, HR was recommended for single HCC
lesions ≤5 cm with preserved liver function, whereas ablation
was proposed for multifocal HCC lesions (2–3 tumours
≤3 cm).3 However, the quality of data for which these recom-
mendations were generated remains poor.4 A major limitation
that has hindered the execution of well-designed randomized
trials has been the difficulty in enrolling a patient cohort that
would be eligible for a treatment approach and the lack of
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adoption of a uniform inclusion criteria.5–7 Moreover, numer-
ous single institution series have compared ablation to HR, but
the definition of what constituted a small HCC has been vari-
able, which probably contributed to the equivocal survival out-
comes reported in the literature.8–13 Among many of the
studies, early stage HCC lesions were typically defined as a sin-
gle T1 lesion up to 5 cm. However, contemporary series along
with a systematic review have since proposed the 3-cm HCC
tumour size as a predictive threshold for ablation efficacy.14,15
Whether or not ablation can achieve a similar outcome as HR
for tumours within the 3-cm range remains ill defined.
Aside from varying tumour sizes, retrospective studies com-
paring HR to ablation have also been problematic given that
most patients that undergo ablation typically have altered liver
function, potentially affecting the prognosis. Even with the use
of multivariate analysis, comparisons between treatment groups
with disparate clinicopathological characteristics may still
underestimate the true treatment effect of a specific therapy.16
The objective of the present study was to compare the efficacy
of ablation to HR for single HCC lesions ≤3 cm by using pro-
pensity score modelling to control for any confounders that
may influence outcomes. It was hypothesized that ablation
resulted in similar long-term outcomes as compared with HR
for a small, single HCC.
Patients and methods
After approval by the Medical College of Wisconsin Institu-
tional Review Board and completion of a data use agreement
with the American College of Surgeons, a retrospective cohort
study was conducted using the National Cancer Data Base
(NCDB). Created as a joint project of the American Cancer
Society and the Commission on Cancer of the American Col-
lege of Surgeons, the NCDB has developed into a comprehen-
sive oncology dataset that captures 70% of all malignancies in
the United States.
Patients with HCC were identified from the NCDB from 2002
to 2011 using the following parameters: site code C22.0 (liver)
and histology codes 8170–8175 (HCC). To ensure that only early
stage, solitary HCC without vascular invasion were included in
the study, patients with T1N0M0 (AJCC 6th/7th edn) disease
were first captured. Patients were then excluded if the tumour
size exceeded 3 cm. The final study cohort consisted of solitary,
≤ 3 cm HCC. The group was then further stratified by type of
treatment, ablation versus resection, according to treatment
codes 11–17 (ablation) and 20–90 (resection). Patients with met-
astatic disease, lymph node positivity, or went on to transplanta-
tion were excluded from the analysis. Data on clinicopathologic
characteristics, including patient age, gender, ethnicity, Charl-
son’s Comorbidity Score (CCS), alpha-fetoprotein level (AFP)
and the presence of cirrhosis were obtained.
Statistical analyses were performed with Stata/MP 10.0 for
Windows (StataCorp, College Station, TX, USA). Continuous
variables were described as medians and interquartile ranges.
Categorical variables were described as totals and frequencies.
Comparisons between treatment arms were conducted using
the Mann–Whitney U-test or chi-squared test as appropriate.
Logistic models were used to evaluate the association of covari-
ates with ablation. Alpha was set at 0.05, and all tests were
two-tailed. Overall survival (OS) was defined as the number of
months from diagnosis to the time of death. Kaplan–Meier
methods and Cox’s proportional hazards modelling were used
to evaluate survival.
To control for the potential treatment effect by covariates,
propensity score (PS) modelling using the greedy matching
algorithm (1 : 1 match) was applied.17 A multivariate logistic
model was constructed, which generated a PS score that
reflected the conditional probability of undergoing ablation.
Results
A total of 2855 patients met inclusion criteria; 1984 patients
(69.5%) underwent ablation versus 871 patients (30.5%) were
resected. In the ablation cohort, the commonest treatments uti-
lized were by a heat-radio-frequency approach (n = 1674,
84.4%), or percutaneous ethanol injection (PEI) (n = 72,
3.6%). Demographic and clinical characteristics for both the
unmatched and propensity-matched cohort by treatment
groups are described in Table 1.
In multivariate models, patients with an elevated AFP [odds
ratio (OR) 1.4, 95% confidence interval (CI): 1.14–1.72,
P < 0.001] or underlying cirrhosis (OR 4.03, 95% CI: 2.83–
5.73, P < 0.001) were independently associated with ablation
(Table 2). Black (OR 0.58, 95%CI: 0.46–0.73, P < 0.001) and
other ethnicities (OR 0.56, 95%CI: 0.45–0.70, P < 0.001) were
less likely to undergo ablation. In light of the marked clinico-
pathological differences between the treatment cohorts, PS
modelling was applied. Variables adjusted in the model
included patient age, gender, race, CCS, AFP level and the
presence of cirrhosis. The final propensity matched cohort
resulted in treatment groups with similar baseline clinicopatho-
logical variables. As reflected in Table 1, PS methods identified
1742 patients [Ablation: 871 patients (50%), Resection: 871
patients (50%)] with similar baseline characteristics.
Overall survival
Unadjusted OS rates at 1, 3 and 5 years were 84%, 52% and
36%, respectively, for patients that underwent ablation, versus
84%, 67% and 55% of resected patients (P < 0.001). After PS
matching, OS remained statistically significant between the two
treatment groups (OS at 1, 3, and 5 years: Ablation 84%, 52%,
36%, Resection 84%, 66%, 54%; P < 0.001, Fig. 1). After mul-
tivariate adjusted Cox’s proportional hazards modelling, a
resection demonstrated a persistent survival benefit as
compared with ablation [hazard ratio (HR): 0.62, 95% CI
0.48–0.81, P < 0.001, Table 3]. Poor prognostic factors included
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older age (HR 1.03, 95% CI 1.02–1.04, P < 0.001) and underly-
ing cirrhosis (HR 1.95, 95% CI 1.01–3.74, P = 0.046). After
excluding patients that underwent PEI and other forms of abla-
tive therapies, subgroup analysis of only those treated by a
heat-radio-frequency approach (n = 732, 84%) demonstrated a
similar survival disadvantage when compared with the resec-
tion cohort (OS at 1, 3 and 5 years: 84%, 49% and 36%,
P < 0.001).
Discussion
Evolving therapies for HCC have contributed to the increasing
complexity surrounding the management of the disease. As
highlighted by the BCLC staging system, both patient- and
tumour-related factors have a major influence on the type of
treatment pursued.3,18 Aside from liver transplantation as an
additional treatment option, in the setting of early stage HCC,
a hepatic resection and ablation remains the cornerstone of
therapy. However, there continues to be an ongoing debate as
to which therapy is most effective for single, early stage HCC
tumours. In this large, population-based cohort, patients with
unifocal ≤3 cm HCC tumours experienced a significant sur-
vival benefit if treated by resection as compared with those that
underwent ablation. Although the data reveals that ablation is
more commonly performed in patients with poor performance
status or the presence of cirrhosis, propensity score modelling
enabled us to control for confounders, while demonstrating a
sustained treatment effect by resection that was superior to
ablation.
Since its introduction, attempts at establishing a tumour size
threshold that could accurately predict outcomes after ablation
has resulted in a spectrum of size cutoffs. Sizes up to 10 cm
have been reported, but the reasoning for these breakpoints
was variable.19 In recent years, ablation series have proposed a
3-cm tumour size as a predictive breakpoint, which was based
on data specific to the ablation technology, and was further
supported by clinical outcomes.14,20 Studies utilizing micro-
wave ablation have demonstrated a mean maximal ablation
diameter of approximately 5.5 cm when using a multiple
antennae approach. For tumours up to 3 cm, this would trans-
Table 1 Demographic and tumour characteristics of patients with hepatocellular carcinoma (HCC) before and after propensity score
matching, 2002–2011
Variable, n (%) Total
(2855)
Unmatched cohort P-value Propensity matched cohort P-value
Ablation
(n = 1984)
Resection
(n = 871)
Ablation
(n = 871)
Resection
(n = 871)
Median Age (IQR) 61 (55–70) 61 (55–70.5) 61 (55–69) 0.267 61 (55–70) 61 (55–69) 0.717
Gender, n (%)
Male 2007 (70.1) 1388 (70) 619 (71.1) 0.551 608 (69.8) 619 (71.1) 0.564
Female 848 (29.9) 596 (30) 252 (28.9) 263 (30.2) 252 (28.9)
Race, n (%)
White 2006 (70.2) 1463 (73.7) 543 (62.3) <0.001 560 (64.3) 543 (62.3) 0.682
Black 396 (13.9) 246 (12.4) 150 (17.2) 145 (16.7) 150 (17.2)
Other 453 (51.9) 275 (13.9) 178 (20.5) 166 (19) 178 (20.5)
Charlson’s Comorbidity Score, n (%)
0 1293 (45.3) 892 (45) 401 (46) 0.045 404 (46.4) 401 (46) 0.976
1 845 (29.6) 568 (28.6) 277 (31.8) 270 (31) 277 (31.8)
≥2 658 (23) 485 (24.4) 173 (19.9) 175 (20.1) 173 (19.9)
Unknown 59 (2.1) 39 (2) 20 (2.3) 22 (2.5) 20 (2.3)
Alpha-fetoprotein level, n (%)
Normal 760 (26.6) 513 (25.9) 247 (28.4) 0.001 233 (26.7) 247 (28.4) 0.414
Elevated 1262 (44.2) 922 (46.5) 340 (39) 328 (37.7) 340 (39)
Unknown 833 (29.2) 549 (27.7) 284 (32.6) 310 (35.6) 284 (32.6)
Cirrhosis, n (%)
No 188 (6.6) 85 (4.3) 103 (11.8) <0.001 84 (9.7) 103 (11.8) 0.335
Yes 571 (20) 441 (22.2) 130 (14.9) 131 (15) 130 (14.9)
Unknown 2096 (73.4) 1458 (73.5) 638 (73.3) 656 (75.3) 638 (73.3)
Median Tumor Size, cm (IQR) 2.2 (1.7–2.6) 2.2 (1.8–2.6) 2.2 (1.7–2.7) 0.824 2.2 (1.8–2.6) 2.2 (1.7–2.7) 0.940
IQR, Interquartile Range.
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late into roughly a 1 cm rim of normal liver parenchyma
incorporated into the ablation zone. Furthermore, the study by
Groeschl et al. utilized the Surveillance, Epidemiology, and
End Results (SEER) Database to capture all patients with sin-
gular HCC tumours that underwent ablation (all types). After
stratifying the patients by 1 cm tumour size intervals, the
authors were able to demonstrate that disease-specific survival
did not vary significantly until tumours were >3 cm. There-
fore, when attempting to compare systematically treatment effi-
cacy between ablation versus resection, it would be logical that
an upper limit of 3 cm for HCC tumours be used among stud-
ies. However, as recently demonstrated in two meta-analyses,
which compared radiofrequency ablation with resection for
early stage HCC, the definition of what constituted a small
HCC remained heterogenous.21,22 Moreover, after pooling the
results of 24 studies, Wang et al. found that overall and dis-
ease-free survival was longer for the resection cohort as com-
pared with patients that underwent ablation when tumours
were greater than 3 cm (5 year OS: OR 0.43, 95%CI 0.25–0.73,
P = 0.002).
In the present study, a predefined breakpoint of 3 cm was
utilized to minimize the potential for an incomplete ablation
associated with larger tumours. Furthermore, only patients
with T1N0M0 (solitary) HCC were identified in an attempt to
limit the influence of tumour biology. When comparing the
two cohorts, unadjusted OS was significantly different, favour-
ing a resection over ablation (5 year OS: 55 versus 36%,
P < 0.001). However, similar to other observational series, abla-
tion was more frequently performed in patients with a poorer
performance status, or a worse liver function, highlighting the
treatment bias that occurs with therapy selection.23,24 Thus, pro-
pensity score modelling was applied, creating treatment cohorts
with similar clinicopathological variables. Despite adjusting for
confounding variables, there remained a persistent survival
advantage among patients receiving HR as compared with abla-
tion, suggesting HR to be the most effective treatment modality
among the two.
A major advantage of large population-based data, such as
the NCDB, is its ability to capture a large cohort, which in
turn improves a study’s generalizability.16 However, when
attempting to compare the efficacy of two therapies, several
individual nuances specific to each treatment, which may have
an impact on outcomes, are often unable to be accounted for
in these registries. If a tumour was located in the periphery
versus centrally located, its proximity to major bile ducts, a
patient’s body habitus, or the provider’s experience has the
potential to influence the outcome of a treatment. Unlike HR,
whereby tumour removal can be confirmed by inspection of
the gross specimen, completeness of ablation is dependent on
the familiarity of ultrasound interpretation. Studies have dem-
onstrated a significant learning curve associated with ablation
therapy.25 Hildebrand et al. found that ablation rates and sur-
vival outcomes were correlated with the number of ablations
performed by the operator. Furthermore, the NCDB is unable
to account for additional operations/procedures a patient may
undergo after the index therapy. Recurrence data are currently
unavailable. As such, the present study is unable to comment
Table 2 Multivariate Logistic Regression of factors associated with
receipt of ablation
Variable OR (95% CI) P-value
Age at diagnosis 1.01 (0.99–1.01) 0.141
Gender
Male Ref –
Female 1.00 (0.83–1.20) 0.992
Race
White Ref –
Black 0.58 (0.46–0.73) <0.001
Other 0.56 (0.45–0.70) <0.001
Alpha-fetoprotein level
Normal Ref –
Elevated 1.40 (1.14–1.72) <0.001
Unknown 0.94 (0.76–1.17) 0.595
Charlson Comorbidity Score
0 Ref –
1 0.89 (0.73–1.07) 0.223
≥2 1.17 (0.94–1.45) 0.161
Unknown 1.07 (0.60–1.90) 0.812
Cirrhosis
No Ref –
Yes 4.03 (2.83–5.73) <0.001
Unknown 2.78 (2.04–3.78) <0.001
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Figure 1 Overall survival comparing surgical resection with
ablation for hepatocellular carcinoma (HCC) ≤ 3 cm after
propensity score matching
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on the role of additional therapies and their impact on sur-
vival.
An additional area lacking in the NCDB is the assessment of
underlying liver disease, which continues to play a critical role
not only in prognosis, but also in treatment selection. At pres-
ent, the NCDB identifies cirrhosis as either being present or
absent. The severity of cirrhosis as described by the Child–Pugh
Classification System is not currently captured. Moreover, site-
specific variables introduced by NCDB, such as cirrhosis, are
often subject to incomplete reporting as demonstrated by
> 70% of the study cohort having an unknown status. Whether
the inability to account for these variables are enough to
explain the significant difference in survival rates between the
two treatments remains ill defined.
Lastly, all types of ablation (i.e. RFA, MWA, ethanol and
cryoablation) were captured in this study, which may have
influenced the outcomes. However, the vast majority of proce-
dures were coded as ‘Heat-Radio-Frequency’ ablation (84%),
which studies have demonstrated to be the most effective
among the various ablation techniques.20 Moreover, in the
subgroup analysis, of only patients that underwent Heat-
Radio-Frequency ablation, there was no statistical change in
the survival difference between ablation compared with a resec-
tion. Unfortunately, owing to coding limitations, the present
study is unable to address the relative efficacy pertaining to a
specific type of thermal ablation (MWA versus RFA).
In conclusion, the present study provides further evidence
supporting HR over ablation for patients with small, unifocal,
HCC tumours. Numerous factors, both patient and tumour
specific, continue to have a major influence on treatment allo-
cation. Therefore, it would be short-sighted to suggest that
ablation has no role for this subset of HCC tumours. Instead,
in the setting of a good surgical candidate, treatment strategies
should continue to emphasize a HR first approach for single,
<3 cm HCC tumours, with ablation being reserved for patients
less suited for the operating room.
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